Aprecia Pharmaceuticals
We partner with pharmaceutical companies to bring innovative, commercial scale 3DP manufacturing capabilities to their existing product portfolios and research pipelines.
APRECIA is The 3DP Pharmaceutical Company. Our proprietary, advanced fast-melt dose form innovation, ZipDose, is the first and only 3DP technology platform used in an FDA approved product. We partner with pharmaceutical companies to bring innovative, commercial scale 3DP manufacturing capabilities to their existing product portfolios and research pipelines. Advanced fast melt, high drug load, modified release, combination drugs are just a few of the possibilities our team can explore with you at AAPS PharmSci360.
Aprecia Pharmaceuticals
10901 Kenwood Road
Blue Ash, OH 45242
513.984.5000
contact@aprecia.com
AAPS Booth Number: 2143
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
